{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:05:51Z","timestamp":1750219551930,"version":"3.41.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jdcr.2025.02.032","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T01:24:13Z","timestamp":1741915453000},"page":"110-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Expanding the potential of monoclonal antibodies against interleukin-4 and interleukin-13 in genodermatoses: A case series on the efficacy and safety of dupilumab in epidermolysis bullosa and ichthyosis"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3583-0816","authenticated-orcid":false,"given":"Francesca","family":"Caroppo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Mazzetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Milan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5014-1122","authenticated-orcid":false,"given":"Fortunato","family":"Cassalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Belloni Fortina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2025.02.032_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1054422","article-title":"Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation","volume":"13","author":"Yan","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jdcr.2025.02.032_bib2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2025.02.032_bib3","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","article-title":"The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use","volume":"132","author":"Lewis-Jones","year":"2010","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2025.02.032_bib4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.anai.2016.07.019","article-title":"Pruritus from allergy skin tests in children: comparing remedies","volume":"117","author":"Stewart","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.jdcr.2025.02.032_bib5","first-page":"7","article-title":"Dupilumab in the treatment of genodermatosis: a systematic review","volume":"21","author":"Wu","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"10.1016\/j.jdcr.2025.02.032_bib6","doi-asserted-by":"crossref","first-page":"T184","DOI":"10.1016\/j.ad.2023.11.010","article-title":"Successful control of recalcitrant pruritus in epidermolysis bullosa pruriginosa with dupilumab","volume":"115","author":"Roque Quintana","year":"2024","journal-title":"Actas Dermosifiliogr"},{"issue":"9","key":"10.1016\/j.jdcr.2025.02.032_bib7","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1111\/jdv.18251","article-title":"Reply to \u201cA case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab\u201d by Caroppo et al","volume":"36","author":"Martora","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jdcr.2025.02.032_bib11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/1346-8138.16729","article-title":"Successful treatment of epidermolysis bullosa pruriginosa by dupilumab","volume":"50","author":"Wu","year":"2023","journal-title":"J Dermatology"},{"issue":"3","key":"10.1016\/j.jdcr.2025.02.032_bib8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jamadermatol.2019.4608","article-title":"Treatment of Netherton syndrome with dupilumab","volume":"156","author":"Steuer","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.jdcr.2025.02.032_bib9","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/ced.14317","article-title":"Successful treatment with dupilumab of an adult with Netherton syndrome","volume":"45","author":"Andreasen","year":"2020","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2025.02.032_bib10","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1111\/jdv.16883","article-title":"Response to dupilumab in two children with Netherton syndrome: improvement of pruritus and scaling","volume":"35","author":"S\u00fc\u00dfmuth","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625001031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625001031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T12:28:05Z","timestamp":1750163285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512625001031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":11,"alternative-id":["S2352512625001031"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.02.032","relation":{},"ISSN":["2352-5126"],"issn-type":[{"type":"print","value":"2352-5126"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding the potential of monoclonal antibodies against interleukin-4 and interleukin-13 in genodermatoses: A case series on the efficacy and safety of dupilumab in epidermolysis bullosa and ichthyosis","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.02.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}